News · 26 weeks114+138%
2026-04-192026-10-11
Mix4390d
- Other18(42%)
- Insider18(42%)
- Dividends3(7%)
- Earnings2(5%)
- SEC Filings2(5%)
Latest news
25 items- INSIDERSEC Form 4 filed by Pfizer Inc.4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Pfizer Inc.4 - PFIZER INC (0000078003) (Issuer)
- PRPfizer Showcases Clinical Advancements Across Infectious Diseases at IDWeek 2026Data from 57 abstracts will highlight Pfizer’s scientific progress targeting infectious diseases, including pneumococcal disease and RSV Pfizer Inc. (NYSE:PFE) will present data from more than 50 company-sponsored, investigator-sponsored and collaborative research abstracts across its infectious disease pipeline and portfolio at the upcoming IDWeek 2026 congress, held in Washington, D.C., from October 21-24, 2026. Data across 12 oral presentations will showcase the Company’s advancements in the prevention and treatment of infectious diseases. "At Pfizer, we address some of the most urgent challenges in infectious diseases, delivering vaccines and anti-infective therapies that protect an
- PRPfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast CancerTUKYSA in combination with trastuzumab and pertuzumab showed more than 50% improvement in median progression-free survival, supporting approval as a chemotherapy-free maintenance option Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive (HER2+) breast cancer following induction treatment. The approval expands the use of TUKYSA to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance treatment option that
- PRAstellas Highlights Data Advancing Cancer Care and Innovation for Patients with Hard-to-Treat Cancers at ESMO 2026– PADCEV™ (enfortumab vedotin) plus pembrolizumab data highlight durable survival benefit in advanced bladder cancer –– VYLOY™ (zolbetuximab) research reinforces the role of CLDN18.2 in shaping gastric cancer treatment decisions –TOKYO, Oct. 6, 2026 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that 21 abstracts from its oncology portfolio will be presented at the European Society for Medical Oncology Congress 2026 (ESMO 2026), taking place October 23–27 in Madrid, Spain. The presentations span prostate, urothelial, gastric/gastroesophageal junction (GEJ), lung and pancreatic cancers, reflecting Astellas' commitment to advanci
- PRPfizer Declares Fourth-Quarter 2026 DividendPfizer Board of Directors approves fourth-quarter 2026 cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2026 dividend on the company’s common stock, payable December 7, 2026, to holders of the Common Stock of record at the close of business on November 6, 2026. As part of its capital allocation strategy, Pfizer is committed to maintaining, and over the longer term, growing the dividend. The fourth-quarter 2026 cash dividend will be the 352nd consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring
- PRPfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental VitiligoLITFULO significantly improved facial and total body repigmentation at Week 52 compared to placebo, with continuous improvement starting at Week 24, supporting planned regulatory filings for a potential new oral systemic therapy for adults with nonsegmental vitiligo Pfizer Inc. (NYSE:PFE) today presented results from two Phase 3 trials evaluating the efficacy and safety of LITFULO® (ritlecitinib) as a once-daily oral treatment across a wide range of disease extent. In the two studies, TRANQUILLO 2 and TRANQUILLO, LITFULO 100 mg and 50 mg, respectively, significantly improved facial and total body repigmentation compared to placebo. These improvements were supported by patient-reported o
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- PRPfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis StudyStudy met primary endpoint, showing a statistically significant increase in the percentage of participants achieving EASI-75 versus placebo at Week 16, for the potentially first-in-class trispecific antibody Pfizer Inc. (NYSE:PFE) today presented detailed results from an ongoing Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate-to-severe atopic dermatitis (AD). The study met its primary endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥75% reduction in the Eczema Area and Severity Index) at Week 16 across all evaluated doses compared to placebo. The findings were shared today in an oral presentati
- FDAFDA Approval for RUXIENCE issued to PFIZER INCSubmission status for PFIZER INC's drug RUXIENCE (SUPPL-20) with active ingredient RITUXIMAB-PVVR has changed to 'Approval' on 09/28/2026. Application Category: BLA, Application Number: 761103, Application Classification:
- FDAFDA Approval for RUXIENCE issued to PFIZER INCSubmission status for PFIZER INC's drug RUXIENCE (SUPPL-20) with active ingredient RITUXIMAB-PVVR has changed to 'Approval' on 09/29/2026. Application Category: BLA, Application Number: 761103, Application Classification:
- INSIDERSEC Form 4 filed by Director Echevarria Joseph4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Buckley Mortimer J4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Narayen Shantanu4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Quincey James4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Taraporevala Cyrus4 - PFIZER INC (0000078003) (Issuer)
- INSIDERSEC Form 4 filed by Director Smith James C4 - PFIZER INC (0000078003) (Issuer)
- PRPfizer Advances Today’s Cancer Care and Tomorrow's Potential Breakthroughs at ESMOData across 45 abstracts will highlight new evidence for established medicines, including PADCEV and TALZENNA, and promising late-stage pipeline candidates such as atirmociclib and tivunatamig (PF’4404) Pfizer Inc. (NYSE:PFE) will present data from 45 company-sponsored, investigator-sponsored, and collaborative research abstracts at the European Society for Medical Oncology (ESMO) Congress, taking place October 23-27, 2026 in Madrid, Spain. The presentations include 11 oral presentations spanning Pfizer’s established medicines and late-stage pipeline across its disease areas of focus, including breast cancer, genitourinary cancers, and lung cancer. "At Pfizer Oncology, we're focused on
- PRPfizer Invites Public to View and Listen to Webcast of November 3 Conference Call with AnalystsPfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 3, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Third Quarter 2026 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confer
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- PRPfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferencePfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Alexandre de Germay, Chief International Commercial Officer, Executive Vice President, at the J.P. Morgan U.S. All Stars 2026 Conference on Tuesday, September 22, 2026 at 11:50 a.m. BST. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at leas
- PRA $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral ThreatNEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Market News Updates News Commentary - The antiviral market is entering a period where the need for new treatments is becoming impossible to ignore. Viral outbreaks can emerge quickly, cross borders and overwhelm healthcare systems before effective therapies are ready. That creates a large and growing commercial opportunity for companies working on drugs that can actually stop viral diseases rather than simply manage their symptoms. The global antiviral drugs market was valued at roughly $42.3 billion in 2025 and is projected to reach approximately $57.8 billion by 2034. But those numbers only tell part of the story. The bigger opportunity may be
- PRPfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferencePfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 10:45 a.m. EDT. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. About Pfi
- INSIDERSEC Form 4 filed by Chairman & CEO Bourla Albert4 - PFIZER INC (0000078003) (Issuer)
- SECSEC Form N-PX filed by Pfizer Inc.N-PX - PFIZER INC (0000078003) (Filer)
PFE FAQ
7 questionsWhat does Pfizer Inc. do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zithromax, Vfend, and Panzyga brands. The company also provides medicines and...Where does PFE stock trade?
Pfizer Inc. (PFE) is listed on NYSE.What sector and industry is PFE in?
Pfizer Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.Does PFE pay a dividend?
Yes. PFE's next ex-dividend date is 2026-11-06 with a declared cash dividend of $0.43 per share, payable 2026-12-07.What are analysts saying about PFE?
Pfizer Inc. has had 8 recent analyst actions on file. The most recent action was from HSBC Securities: Hold with a $2800.00 price target on 2026-07-06. Recent price targets range from $2500.00 to $3500.00.What companies are similar to PFE?
Notable peers in the same industry include JNJ (Johnson & Johnson), MRK (Merck & Company Inc.), NVS (Novartis AG), AZN (AstraZeneca PLC), GSK (GSK plc). Compare PFE side-by-side with any of them on Quantisnow.How can I track PFE on Quantisnow?
Quantisnow aggregates Pfizer Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow PFE to receive live email and push alerts on every new disclosure.